AU2018345683B2 - Modified Cpf1 guide RNA - Google Patents

Modified Cpf1 guide RNA Download PDF

Info

Publication number
AU2018345683B2
AU2018345683B2 AU2018345683A AU2018345683A AU2018345683B2 AU 2018345683 B2 AU2018345683 B2 AU 2018345683B2 AU 2018345683 A AU2018345683 A AU 2018345683A AU 2018345683 A AU2018345683 A AU 2018345683A AU 2018345683 B2 AU2018345683 B2 AU 2018345683B2
Authority
AU
Australia
Prior art keywords
sequence
nucleic acid
crrna
cpfl
extension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018345683A
Other languages
English (en)
Other versions
AU2018345683A1 (en
Inventor
Kunwoo Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genedit Inc
Original Assignee
Genedit Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genedit Inc filed Critical Genedit Inc
Publication of AU2018345683A1 publication Critical patent/AU2018345683A1/en
Priority to AU2025202594A priority Critical patent/AU2025202594A1/en
Application granted granted Critical
Publication of AU2018345683B2 publication Critical patent/AU2018345683B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2018345683A 2017-10-02 2018-10-02 Modified Cpf1 guide RNA Active AU2018345683B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202594A AU2025202594A1 (en) 2017-10-02 2025-04-11 Modified Cpf1 guide RNA

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762567123P 2017-10-02 2017-10-02
US62/567,123 2017-10-02
US201862617138P 2018-01-12 2018-01-12
US62/617,138 2018-01-12
US201862697327P 2018-07-12 2018-07-12
US62/697,327 2018-07-12
PCT/US2018/054027 WO2019070762A1 (en) 2017-10-02 2018-10-02 RNA GUIDE CPF1 MODIFIED

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202594A Division AU2025202594A1 (en) 2017-10-02 2025-04-11 Modified Cpf1 guide RNA

Publications (2)

Publication Number Publication Date
AU2018345683A1 AU2018345683A1 (en) 2020-04-23
AU2018345683B2 true AU2018345683B2 (en) 2025-05-08

Family

ID=64184173

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018345683A Active AU2018345683B2 (en) 2017-10-02 2018-10-02 Modified Cpf1 guide RNA
AU2025202594A Pending AU2025202594A1 (en) 2017-10-02 2025-04-11 Modified Cpf1 guide RNA

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202594A Pending AU2025202594A1 (en) 2017-10-02 2025-04-11 Modified Cpf1 guide RNA

Country Status (11)

Country Link
US (1) US20200299689A1 (cg-RX-API-DMAC7.html)
EP (1) EP3692154A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020537540A (cg-RX-API-DMAC7.html)
CN (2) CN111770994B (cg-RX-API-DMAC7.html)
AU (2) AU2018345683B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006601A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077189A1 (cg-RX-API-DMAC7.html)
IL (2) IL273595B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003339A (cg-RX-API-DMAC7.html)
SG (1) SG11202003083PA (cg-RX-API-DMAC7.html)
WO (1) WO2019070762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
WO2018209158A2 (en) 2017-05-10 2018-11-15 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US11268092B2 (en) 2018-01-12 2022-03-08 GenEdit, Inc. Structure-engineered guide RNA
WO2019178426A1 (en) * 2018-03-14 2019-09-19 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
GB201905651D0 (en) * 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
GB201913997D0 (en) * 2019-09-27 2019-11-13 Oxford Nanopore Tech Ltd Method
WO2021127594A1 (en) * 2019-12-18 2021-06-24 Editas Medicine, Inc. Engineered cells for therapy
CN113234701B (zh) * 2020-10-20 2022-08-16 珠海舒桐医疗科技有限公司 一种Cpf1蛋白及基因编辑系统
WO2022125329A1 (en) * 2020-12-07 2022-06-16 Inscripta, Inc. gRNA STABILIZATION IN NUCLEIC ACID-GUIDED NICKASE EDITING
WO2023201270A2 (en) * 2022-04-13 2023-10-19 Caribou Biosciences, Inc. Therapeutic applications of crispr type v systems
US20240167029A1 (en) * 2022-06-27 2024-05-23 University Of Massachusetts Modified guide rnas for crispr genome editing
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025212120A1 (en) * 2024-04-05 2025-10-09 Arbor Biotechnologies, Inc. Chemical modifications of guide rnas for crispr nucleases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070598A1 (en) * 2015-10-23 2017-04-27 Caribou Biosciences, Inc. Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
WO2018204493A1 (en) * 2017-05-04 2018-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for gene editing in t cells using crispr/cpf1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
CN106244591A (zh) * 2016-08-23 2016-12-21 苏州吉玛基因股份有限公司 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070598A1 (en) * 2015-10-23 2017-04-27 Caribou Biosciences, Inc. Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
WO2018204493A1 (en) * 2017-05-04 2018-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for gene editing in t cells using crispr/cpf1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INES FONFARA ET AL: "The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRIPSR RNA", NATURE, vol. 532, 20 April 2016 (2016-04-20), pages 517-521, DOI: 10.1038/nature17945 *

Also Published As

Publication number Publication date
CA3077189A1 (en) 2019-04-11
IL323269A (en) 2025-11-01
AU2025202594A1 (en) 2025-05-22
CN120290559A (zh) 2025-07-11
JP2024116119A (ja) 2024-08-27
WO2019070762A1 (en) 2019-04-11
SG11202003083PA (en) 2020-05-28
AU2025202594A9 (en) 2025-09-04
IL273595A (en) 2020-05-31
JP2020537540A (ja) 2020-12-24
MX2020003339A (es) 2020-11-06
IL273595B1 (en) 2025-10-01
CN111770994B (zh) 2025-03-18
KR20200106485A (ko) 2020-09-14
EP3692154A1 (en) 2020-08-12
BR112020006601A2 (pt) 2020-12-08
US20200299689A1 (en) 2020-09-24
CN111770994A (zh) 2020-10-13
AU2018345683A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
AU2018345683B2 (en) Modified Cpf1 guide RNA
AU2017373797B2 (en) Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA
AU2023266284A1 (en) CRISPR/Cpf1-related methods, compositions and components for cancer immunotherapy
AU2018346527B2 (en) Systems, methods, and compositions for targeted nucleic acid editing
US11268092B2 (en) Structure-engineered guide RNA
AU2017291960B2 (en) Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
US20200347387A1 (en) Compositions and methods for target nucleic acid modification
CA3026112A1 (en) Cpf1 complexes with reduced indel activity
AU2014362245A1 (en) Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
WO2016094874A1 (en) Escorted and functionalized guides for crispr-cas systems
CN112585268A (zh) 通过插入供体多核苷酸用于基因组编辑的组合物和方法
JP2023531384A (ja) 新規なｏｍｎｉ－５９、６１、６７、７６、７９、８０、８１及び８２クリスパーヌクレアーゼ
TW202333747A (zh) 調節ｐｃｓｋ９之方法及其用途
KR20240135610A (ko) Omni-103 crispr 뉴클레아제-rna 복합체
JP2024506608A (ja) Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ
KR102907044B1 (ko) 변형된 cpf1 가이드 rna
KR20220005411A (ko) 질환 세포-특이적인 miRNA에 의해 세포 생리 활성 조절 물질의 활성을 조절하는 복합체 및 이를 CRISPR/Cas 시스템에 적용한 질환 특이적 유전자 조작용 복합체
US20240425850A1 (en) Noncanonical crRNA for Highly Efficient Genome Editing
CN120500535A (zh) Omni-335 crispr核酸酶
EP4646475A1 (en) Activated bec nucleases for degrading nucleic acid molecules
Pi RNA Nanotechnology for Next Generation Targeted Drug Delivery
EA047582B1 (ru) Модифицированная направляющая рнк cpf1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)